 "Suven Life Sciences surges on securing patents for neurodegenerative drug")
Shares of Suven Life Sciences have moved higher by 6% to Rs 249 on the BSE after the drug firm said it has secured patents in China and South Africa for a drug used in the treatment of neurodegenerative diseases.
“The company secured patents in China and South Africa to its New Chemical Entities (NCE’s) for CNS therapy through mechanism of action – H3 Inverse agonist and these patents are valid until 2031, 2030 and 2031 respectively,” Suven Life Sciences said in a news release.
The granted claims of the patent include the class of selective H3 ligands discovered by Suven and are being developed as therapeutic agents and are useful in the treatment of cognitive impairment associated with neurodegenerative disorders, it added.
Neurodegenerative diseases include Alzheimer's, Schizophrenia and Parkinson's.
The stock opened at Rs 235 and hit a high of Rs 252 on the BSE. The trading volumes on the counter more than doubled with a combined 1.35 million shares changed hands on the BSE and NSE till 1056 hours.
“The company secured patents in China and South Africa to its New Chemical Entities (NCE’s) for CNS therapy through mechanism of action – H3 Inverse agonist and these patents are valid until 2031, 2030 and 2031 respectively,” Suven Life Sciences said in a news release.
The granted claims of the patent include the class of selective H3 ligands discovered by Suven and are being developed as therapeutic agents and are useful in the treatment of cognitive impairment associated with neurodegenerative disorders, it added.
Neurodegenerative diseases include Alzheimer's, Schizophrenia and Parkinson's.
The stock opened at Rs 235 and hit a high of Rs 252 on the BSE. The trading volumes on the counter more than doubled with a combined 1.35 million shares changed hands on the BSE and NSE till 1056 hours.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%